Arthur D. Little Study Establishes Precise Impact of AI on Development and Engineering and Outlines Concrete Actions to Drive Success
19.2.2025 10:00:00 CET | Business Wire | Press release
Harnessing AI will transform development and engineering functions – but success requires organizations to reshape themselves. That is one of key findings of a major Arthur D. Little (ADL) report, which highlights how AI can contribute to 25% growth and 60% productivity gains by 2030 across the innovation cycle, and provides concrete actions for companies to take now.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219240347/en/
Arthur D. Little's new report outlines a roadmap for embedding AI in development and engineering. (Photo: Business Wire)
The in-depth, comprehensive study, carried out with NAE (Netherlands Academy of Engineering), IVA (Royal Swedish Academy of Engineering Sciences), and KIVI (Koninklijk Instutuut van Ingenieurs), is based on information from over 900 AI and technology case studies, multiple hands-on projects, and survey feedback from 95 respondents across industries including high-tech, manufacturing, processing, pharmaceuticals and healthcare, defense, energy, and logistics.
Driven by changing customer demands that increase complexity, stricter regulatory requirements, and a fundamental shift from products to heterogenous solutions built on diverse technological domains, development and engineering must transform. Doing nothing is not an option.
AI is central to addressing these challenges, and the study has captured and curated a highly mature ecosystem of over 3,500 solution providers. This unique database helps show the complete field of possibilities for development and engineering teams. However, to maximize impact, AI tools must be deployed in conjunction with new ways of working – adopting a people-centric approach is vital. This requires organizations to develop capabilities, encourage appropriate mindsets, and enhance trust in AI’s reliability, explainability, and security.
The report outlines actionable recommendations, including a roadmap for embedding AI in development and engineering. This starts by building a balanced portfolio of AI applications, which should then be actioned using the Networked Lab of the Future, a four-step transformation approach. This includes empowering people through the adoption of AI (democratization) and leveraging internal and external data (data collaboration) to drive success.
Michaël Kolk, Managing Partner and Global Innovation Practice Leader at Arthur D. Little, comments: “Development and engineering is transforming, requiring new ways of working and new skills and capabilities. AI underpins this. While many high level reports outline AI’s theoretical potential, our study goes further, providing tangible actions that organizations can take now to realize the benefits of AI integration.”
Download the report here: https://tinyurl.com/5a52ed8c
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219240347/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom